Prothena Corporation plc Stock Price and Value Analysis

Should you buy Prothena Corporation plc stock? (NasdaqGS:PRTA). Let's see how it does in our automated value investing analysis system.

  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the PRTA Numbers

PRTA Price
(Prothena Corporation plc stock price per share)
[?] PE Ratio versus Sector 2% lower than other Healthcare stocks
[?] PE Ratio versus Industry 65% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 50%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,715,982 shares shorted. With 21,202,078 shares available for purchase and an average trading volume over the past 10 trading days of 560,100, it would take at least 4.849 days for all of the short holders to cover their shorts.

Is Prothena Corporation plc Stock on Sale?

Based on our analysis, we believe that you should not buy Prothena Corporation plc right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy PRTA Stock?

Does Prothena Corporation plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.